

# Xbrane Biopharma certified as a Great Place to Work®

**Based on the results of a company-wide employee survey Xbrane Biopharma has been officially awarded the Great Place to Work® certificate by the Great Place to Work® Institute**

**Solna, Sweden July 2, 2021.** Xbrane Biopharma ("Xbrane"), a biosimilar developer with the aim to make biological drugs affordable for wider patient populations globally, today announces its certification to a Great Place to Work® 2021 by the independent institute Great Place to Work®, a global authority on workplace culture and leadership behaviours. The certification is primarily based on ratings provided by Xbrane employees in an anonymous survey called Trust Index™ that assesses perspectives on leadership, pride and teamwork.

*"We are very pleased that Xbrane has been certified as a Great Place to Work®. We strive to become a purpose-driven organization with strong values, which I think is reflected in our high Trust Index™. This is an important foundation for the future success of the company, and to fulfil our goal - to become the most attractive employer within our field",* says Martin Åmark, CEO.

95 percent of Xbrane's employees participated in the Great Place to Work® survey. The cornerstones of the company's culture are: "Make it happen", "Beat yesterday", "Impossible is nothing" and "We win as one".

## **About Great Place to Work®**

Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees around the world and used those deep insights to define what makes a great workplace. Their unparalleled benchmark data is used to recognize Great Place to Work-Certified™ companies and the Best Workplaces™ in more than 60 countries, including the 100 Best Companies to Work For® and World's Best list published annually in Fortune. Everything they do is driven by the mission to build a better world by helping every organization become a Great Place to Work for All™. To learn more, visit [www.greatplacetowork.com](http://www.greatplacetowork.com).

## **Contacts**

Martin Åmark, CEO

M: +46 76 309 37 77

E: [martin.amark@xbrane.com](mailto:martin.amark@xbrane.com)

Anette Lindqvist, CFO/IR

M: +46 76 325 60 90

E: [anette.lindqvist@xbrane.com](mailto:anette.lindqvist@xbrane.com)

---

## About Us

---

*Xbrane Biopharma AB develops biological drugs based on a platform technology that provides significantly lower production costs compared to competing systems. Xbrane's leading product Xlucane™, a Lucentis® biosimilar candidate, addresses the € 10.4bn ophthalmic VEGFa inhibitor market. Marketing authorization of Xlucane™ is expected for the second half of 2022. Xbrane has additionally two biosimilars in its pipeline targeting € 7.9bn in originator sales. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit [www.xbrane.com](http://www.xbrane.com).*

## Attachments

---

[Xbrane Biopharma certified as a Great Place to Work®](#)